All In MedTech

Device Trial Radar · NCT02453373

Helping Stroke Patients With ThermoSuit Cooling

Last checked: Nov 20, 2026Latest source record: Jun 6, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

14

Actual

Start

Jan 25, 2017

Primary completion

Jun 1, 2023

Study completion Jun 2, 2023

Sponsor

Lead sponsor
Life Recovery SystemsAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Tulane University School of Medicine; Geisinger Clinic
First posted
May 25, 2015

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Non randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this study is to assess the feasibility of using the Life Recovery Systems ThermoSuit Device to induce therapeutic hypothermia (32-34°C) in victims of ischemic stroke. This feasibility clinical study will enroll a total of 30 patients with acute ischemic stroke at four clinical centers. Subjects will receive hypothermia plus conventional therapy (such as IV-tPA and/or neurothrombectomy therapies if indicated). Endpoints will include feasibility of cooling, adverse events, and neurological recovery in comparison with matched historical controls.

Conditions

  • Stroke
  • Brain Ischemia

Interventions

  • ThermoSuit Cooling InductionDevice

    Rapid induction of therapeutic hypothermia (32-34 degrees C) using the Life Recovery Systems ThermoSuit System

  • Magnesium SulfateDrug

    Magnesium sulfate will be administered intravenously as needed to control shivering

  • tPADrug

    tPA will be administered intravenously if indicated

  • PropofolDrug

    Induction doses of propofol or etomidate will be used to aid in the suppression of patient discomfort

  • EtomidateDrug

    Induction doses of propofol or etomidate will be used to aid in the suppression of patient discomfort

  • NeurothrombectomyProcedure

    If indicated, neurothrombectomy will be performed using an FDA-cleared device within the FDA-cleared treatment window.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Feasibility of cooling as indicated by percentage of patients cooled to target within 1 hour of start of coolingTime frame: 1 hour after start of cooling

5 more outcomes with a free account

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Tulane University

    New Orleans, Louisiana

3 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.